Résumé
The HIV-1 prime boost phase I/II vaccine trial using a recombinant canarypox vector, vCP1521, containing subtype E env (gp120), and subtype B env (gp41), gag and protease has started in Thailand. We have demonstrated that although 4 from 15 human immunodeficiency virus type 1 (HIV-1) seronegative Individuals showed cytotoxic T lymphocyte (CTL) responses to vaccinia virus antigens, none of them showed specific CTL responses to subtype E Env after in vitro stimulation. This preliminary study suggests that specific CTL responses to subtype E envelope detected in HIV-1 seronegative Individuals after vaccination should be considered as specific responses to the immunization.
Sujets)
Adulte , Antigènes viraux/immunologie , Lymphocytes B/immunologie , Femelle , Antigènes du VIH/immunologie , Protéine d'enveloppe gp120 du VIH/immunologie , Séronégativité VIH/immunologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/immunologie , Herpèsvirus humain de type 4/immunologie , Humains , Immunophénotypage , Mâle , Adulte d'âge moyen , Valeurs de référence , Sensibilité et spécificité , Lymphocytes T cytotoxiques/immunologie , Thaïlande , Virus de la vaccine/immunologieRésumé
Nasopharyngeal carcinoma (NPC) is strongly associated with Epstein-Barr virus (EBV) infection. To assess whether EBV DNA detection by polymerase chain reaction (PCR) or presence of specific serum antibody to viral capsid antigen (VCA) was a better marker for screening NPC, nasopharyngeal tissues and blood samples from 58 NPC patients and 24 non-NPC patients (23 with laryngotracheal stenosis and 1 with chronic tonsillitis) were tested for the presence of EBV DNA and serum specific VCA antibodies, respectively. EBV DNA was detected in 56 (96.5%) of NPC patients and 15 (62.5%) of non-NPC controls, with predominantly EBV type A in both groups. On the other hand, specific VCA IgA antibody was detected in the majority of NPC patients: 52 (89.7%) while only 4 (16.7%) were detected in non-NPC controls. Therefore, specific VCA IgA antibody may serve as a better marker for screening NPC than EBV DNA detected by PCR.
Sujets)
Anticorps antiviraux/sang , Antigènes viraux/génétique , Marqueurs biologiques , Protéines de capside , ADN viral/analyse , Infections à virus Epstein-Barr/diagnostic , Humains , Immunoglobuline A/sang , Dépistage de masse/méthodes , Tumeurs du rhinopharynx/diagnostic , Réaction de polymérisation en chaîne , Valeur prédictive des tests , Sensibilité et spécificitéRésumé
A total of 62 clinical specimens from the genital tract of patients who were suspected of contracting genital herpes were investigated for HSV infection by the virus isolation method, and also investigated for the co-infection with EBV infection by detecting EBV DNA using nested PCR. HSV infection was diagnosed in 30 (48.4%) of the study cases, and so was EBV. EBV DNA was present in 17 (56.7%) of the 30 HSV positive samples. No correlation was found between the co-existence of these two viruses together. EBV DNA was detected in genital specimens of cervical, vaginal, urethral, and anal swabs. Ninety per cent of EBV belonged to type 1, and the remainder belonged to type 2 and mixed types. The role of EBV in genital tract infection needs to be further investigated.